Teva Archives | Be Korea-savvy

Home / Posts tagged Teva

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinics The program, launching this month, will run for a minimum of three years PARSIPPANY, N.J., Dec. 11, 2024 (Korea Bizwire) – Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of a new patient access [...]

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Teva entered into an agreement with JKI Co., Ltd. (“JKI”) established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. (“J-Will”), through which JKI will acquire Teva-Takeda The agreement is aligned with Teva’s Pivot to Growth strategy to focus its business The expected divestment of Teva-Takeda, Teva’s business venture in Japan, [...]

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

TEL AVIV, Israel, Nov. 25 (Korea Bizwire) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, and Eric Hughes, Teva’s Executive Vice President of Global R&D and Chief Medical Officer, will present at the 7th Annual Evercore ISI HealthCONx Conference on Thursday, December 5, 2024. The presentation [...]

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Prolia® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal women TVB-009P, Teva’s proposed biosimilar to Prolia, showed Phase 3 clinical results in osteoporosis and is part of Teva’s robust biosimilar portfolio – 7 approved biosimilars and 16 in the pipeline – across critical therapeutic areas such [...]

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024 The collaboration supports Teva’s Pivot to Growth strategy and adds to the company’s biosimilar portfolio Both companies reaffirm their shared commitment to making high-quality, affordable treatments accessible to patients worldwide TEL AVIV, ISRAEL and MADRID, Oct. [...]

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

TEL AVIV, Israel, Sept. 30 (Korea Bizwire) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the third quarter of 2024 on Wednesday, November 6, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live [...]

Teva to Present at the Bank of America 2024 Global Healthcare Conference

TEL AVIV, Israel, Sept. 11 (Korea Bizwire) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will present at the Bank of America 2024 Global Healthcare Conference on Thursday, September 19, 2024. The presentation will begin at 8.15 A.M. British summer time (3.15 A.M. Eastern Time). [...]

Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

TEL AVIV, Israel, Aug. 26 (Korea Bizwire) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. The presentation will begin at 11:30 A.M. Eastern Time. To access a live webcast of [...]

Essential Pharma Acquires European Rights to Colobreathe®(colistimethate sodium) from Teva

Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Colobreathe® is an inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients The acquisition will help ensure continued access to an important medicine for this vulnerable patient population First rare disease medicine to be added to the Essential Pharma product portfolio [...]

Celltrion Clinches 110 bln-won Drug Substance Supply Deal from Teva

SEOUL, Aug. 19 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday it has secured a 110 billion-won (US$83 million) drug substance supply deal from Teva Pharmaceutical Industries Ltd. for use in producing the Israel-based generic drugmaker’s migraine medicine. Under the contract manufacturing organization (CMO) deal, Celltrion will provide drug substance [...]